EQT Completes Historic Exit from Galderma Group AG with Record Block Trade EQT has finalized its exit from Galderma through the largest sponsor-backed block trade in history, solidifying its successful investment strategy.

EQT Completes Historic Exit from Galderma Group AG with Record Block Trade #EQT #Stockholm #Switzerland #IPO #Galderma

Shit. Wenn erfolglose Fondsmanager #Galderma jetzt entdecken, muss ich mich wohl so langsam verabschieden.

Der Dermatologiekonzern #Galderma überzeugt mit einem starken Ausblick und heraufgesetzten Mittelfristzielen.

Lesen Sie die Analyse von Miriam Kappeler hier: www.fuw.ch/galderma-tra...

Bild: Oleksandra Polishchuk/iStock/Getty Images

L’Oréal vergroot belang in Galderma tot 20 procent: inzet op dermatologie neemt toe Key takeaways L’Oréal heeft een strategische stap aangekondigd om haar partnerschap met Galderma, een toonaangevende speler op de dermatologiemarkt, te versterken. Het bedrijf zal een extra belang van 10 procent in Galderma verwerven van een consortium onder leiding van EQT, waarmee het totale belang op 20 procent komt. Met deze investering toont L’Oréal haar betrokkenheid […]

L’Oréal vergroot belang in Galderma tot 20 procent: inzet op dermatologie neemt toe #LOréal #Galderma #Dermatologie #Esthetiek #Investering

L’Oréal augmente sa participation dans Galderma à 20 pour cent : engagement accru dans le domaine de la dermatologie Principaux renseignements L’Oréal a annoncé un mouvement stratégique visant à renforcer son partenariat avec Galderma, un acteur de premier plan sur le marché de la dermatologie. L’entreprise va acquérir une participation supplémentaire de 10 pour cent dans Galderma auprès d’un consortium dirigé par EQT, ce qui portera sa participation totale à 20 pour cent. Cet […]

L’Oréal augmente sa participation dans Galderma à 20 pour cent : engagement accru dans le domaine de la dermatologie #LOréal #Galderma #Dermatologie #Business #Investissement

EQT Finalizes Agreement for Sale of Galderma Shares to L'Oréal EQT has reached a significant agreement to sell approximately 24 million shares in Galderma Group AG to L'Oréal S.A., promising industry shifts.

EQT Finalizes Agreement for Sale of Galderma Shares to L'Oréal #EQT #None #L'Oréal #Galderma

EQT Successfully Completes Major Share Sale of Galderma Group AG, Raising Over CHF 2.6 Billion EQT VIII has finalized the sale of 20 million shares in Galderma Group AG, earning significant gross proceeds of approximately CHF 2.6 billion, marking a substantial financial move.

EQT Successfully Completes Major Share Sale of Galderma Group AG, Raising Over CHF 2.6 Billion #Stockholm #Switzerland #stock_sale #EQT_VIII #Galderma

Thinking about Skin-Quality Injectables? Start Here. When do you know it’s time for injectables? It’s a question that many adults may have asked themselves at one point—and it’s not just reserved for a specific age bracket anymore. For some, it’s about dullness that no skin-care routine seems to fix. For others, it’s the start of fine lines or an overall loss […] The post Thinking about Skin-Quality Injectables? Start Here. first appeared on Allure Philippines.

A Estética Injetável Como Aliada da Longevidade da Pele Forbes, a mais conceituada revista de negócios e economia do mundo. Galderma apresenta em evento novas técnicas, abordagens e produtos para atender as últimas tendências de estética injetável O post A Estética Injetável Como Aliada da Longevidade da Pele apareceu primeiro em Forbes Brasil.

EQT Concludes Successful Sale of Shares in Galderma Group AG EQT has finalized the sale of 17 million shares in Galderma Group AG, resulting in gross proceeds of approximately CHF 2.1 billion. The strategic placement enhances EQT's investment portfolio.

EQT Concludes Successful Sale of Shares in Galderma Group AG #Sweden #EQT #Investment #Stockholm #Galderma

Galderma CFO Thomas Dittrich to depart GALD hereremove ads Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #Galderma #CFO #ThomasDittrich #FinanceNews #BusinessUpdate

UBS downgrades Galderma to “neutral” on valuation concerns, softer aesthetics Investing.com -- UBS has downgraded Galderma Group AG (SIX:GALD) to “neutral” from “buy,” citing limited upside following strong share price performance, in a note dated Monday. The decision reflects a more cautious stance on the injectable aesthetics segment and concerns over a demanding valuation. The 12-month price target was cut to CHF120 from CHF128, primarily due to foreign exchange effects. The UBS 2Q25 U.S. Aesthetics Survey, which polled 61 practitioners, showed ongoing strength in neuromodulators but flagged a downturn in other categories. Neuromodulator growth is projected at 7.1% over the next six months, slightly down from 7.7% in December 2024. Fillers are expected to contract by -0.5%, compared to prior expectations of 6.2% growth, while biostimulators are forecast to grow 3.6%, down from 6.9%. The survey also found a rise in promotional activity, with 25% of respondents reporting increased discounting and marketing efforts. UBS expects Galderma’s second quarter results to reflect these trends, with a slowdown in neuromodulators and a partial recovery in fillers. The company’s 1Q25 injectable aesthetics growth of 9.9% constant exchange rate (CER) was driven by a 21.4% rise in neuromodulators, while fillers and biostimulators declined 2.3%. A normalization is anticipated in 2Q25 as U.S. neuromodulator stocking effects reverse. Despite strong early results for Nemluvio, UBS maintained its peak sales forecast at $3 billion. U.S. prescriptions grew over 110% sequentially in 2Q, but UBS models only 70% sales growth due to declining units per prescription and increased rebates, particularly in atopic dermatitis. UBS estimates 2Q25 Nemluvio sales 18% above consensus and FY25 sales 25% ahead. Galderma’s valuation was flagged as a concern. The company trades at 25.6x 2026E EV/EBITDA and 20.6x excluding Nemluvio, representing a 73% and 36% premium, respectively, over Swiss therapeutic peers Straumann and Alcon (NYSE:ALC). UBS continues to use a sum-of-the-parts methodology, valuing the base business at 20x 2026E EV/EBITDA and assigning Nemluvio a standalone net present value. In financial terms, Galderma is forecast to report revenues of $4.91 billion in 2025, rising to $5.66 billion in 2026. UBS projects core EBITDA of $1.10 billion for 2025, with a margin of 22.6%, and net earnings of $615 million. EPS is expected to reach $2.59 in 2025 and $3.88 in 2026. Net debt is projected to fall from $2.31 billion in 2024 to $1.99 billion in 2025.

Click Subscribe #UBS #Galderma #StockMarket #InvestmentNews #Aesthetics

Galderma Launches New U.S. Headquarters in Miami to Amplify Growth Galderma announces the opening of its new U.S. headquarters in Miami, aiming to accelerate growth in the dermatology sector with a vibrant local market.

Galderma Launches New U.S. Headquarters in Miami to Amplify Growth #United_States #Miami #dermatology #Galderma

Click Subscribe #Galderma #StockMarket #Investing #Shares #Finance

Immunology Weekly News – April 30th 2025 🧠 This Week in Immunology: Record Sales, FDA Approvals, and Autoimmune Innovation Catch the latest headlines shaping immunology—from groundbreaking trials […] The post Immunology Weekly News – April 30th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Immunology Weekly News – April 30th 2025 #News #dermatology #autoimmunediseases #Galderma Comment below!

Immunology Weekly News – April 30th 2025 🧠 This Week in Immunology: Record Sales, FDA Approvals, and Autoimmune Innovation Catch the latest headlines shaping immunology—from groundbreaking trials […] The post Immunology Weekly News – April 30th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Immunology Weekly News – April 30th 2025 #News #dermatology #autoimmunediseases #Galderma Comment below!

Immunology Weekly News – April 30th 2025 🧠 This Week in Immunology: Record Sales, FDA Approvals, and Autoimmune Innovation Catch the latest headlines shaping immunology—from groundbreaking trials […] The post Immunology Weekly News – April 30th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Immunology Weekly News – April 30th 2025 #News #dermatology #autoimmunediseases #Galderma Comment below!

Galderma Introduces Campaign to Address the Hidden Struggles of Atopic Dermatitis Galderma's 'Scratch Resistance' campaign sheds light on the emotional and physical effects of atopic dermatitis, encouraging treatment options for those affected.

Galderma Introduces Campaign to Address the Hidden Struggles of Atopic Dermatitis #USA #Boston #Atopic_Dermatitis #Galderma #NEMLUVIO

Differin's Innovative Roblox Campaign Aims to Destigmatize Acne Treatment for Teens Galderma's Differin has launched a groundbreaking campaign on Roblox, aiming to educate and empower teens about acne care while destigmatizing treatment through gaming.

Differin's Innovative Roblox Campaign Aims to Destigmatize Acne Treatment for Teens #USA #Miami #Roblox #Galderma #Differin

Galderma & Co: Mögliche Kaufgelegenheit für Schnäppchenjäger nach Aktienplatzierung Trennen sich Grossaktionäre von Aktienpaketen, war dies in der Vergangenheit ein guter Einstiegszeitpunkt für Investoren. Das könnte auch bei Galderma erneut so sein.

Daher weht der Wind bei #Galderma - Aktienplatzierung von Großaktionären
www.cash.ch/news/top-new...

#Galderma Update
Die Zahlen am 6. März waren gut. US Zölle könnten belasten.
Bin gespannt, was die Aktie nächste Woche macht.

Galderma Reports Record $4.41B Revenue in 2024, Projects 10-12% Growth for 2025 | AI News Brew <p>Swiss dermatology giant Galderma Group AG reported record financial results for 2024, with net sales reaching $4.41 billion, representing a 9.3% year-over-year growth at constant currency [1]. The ...

Galderma Reports Record $4.41B Revenue in 2024, Projects 10-12% Growth for 2025 haiku.ainewsbrew.com/article/3375

#Galderma #HealthcareStocks #DermatologyIndustry #CorporateEarnings #SwissBusiness #MedicalIndustry #FinancialResults #BusinessGrowth #Skincare #InvestmentNews

Nemluvio® by Galderma: FDA Greenlights Revolutionary Itch-Relief Therapy Galderma has achieved a significant milestone with the U.S.

www.linkedin.com/pulse/nemluv...

Nemluvio® by Galderma: FDA Greenlights Revolutionary Itch-Relief Therapy

kstrategyand.com/pharma-news

#FDAApproval #Nemluvio #Galderma #AtopicDermatitis #EczemaTreatment #InnovativeMedicine #HealthcareInnovation #Humanteconomy #Humantec #KStrategyand

📅10/12/2024 | Atualização no Instagram Feed: gun_atthaphan

🩵

#Galderma #ThisisMylook
#LYFTYourLookLiftYourLife
#NASHA #OBT #Dermalfiller
#กันอรรถพันธ์ #GunAtthaphan
#ออฟกัน #OffGun

🚨 Oferta Amazon!

👉 Skin Week: Galderma. Aproveite as ofertas:
🛒 amzn.to/3MYzdSv 🧴

🚛 Frete Grátis membros Prime
✨ Assine o Prime:
amzn.to/3B6g66u
📚 3 meses Grátis de Kindle Unlimited!
amzn.to/3XLQftj

#amazon #prime #oferta #sdv #skinweek #galderma